Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03704467 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.

NCT NCT03704467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03704467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 4, 2019
Completion date
November 6, 2019
Enrollment
3 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer